OurView Tirzepatide Review: Prepaid Price & Charge Timing

OurView’s named compounded tirzepatide page lists $129 month-to-month or $357 paid today for three months, equivalent to $119 per month. The prepaid amount is a complete three-month payment, not three monthly installments. The page advertises one price across prescribed doses and a 30-day medication supply shipped every 30 days.³

Match the supplied medication to the commitment

The product description says its GLP-1 compounds include glycine. Confirm your actual prescribed ingredients, concentration, supplied quantity and administration instructions. A monthly equivalent, general product image or public availability label does not establish an individual prescription or eligibility.³

The FAQ says payment is authorized at checkout but collected only after provider approval; a declined treatment releases the authorization without a charge. This initial approval rule does not establish the later renewal schedule or whether future charges are automatic. Ask how a monthly or prepaid plan continues and how to stop an order already being reviewed.⁴

The January 9, 2026 terms let patients request a different pharmacy before completing an order. Obtain any resulting cost and fulfillment change in writing rather than assuming the same bundled price applies.⁶

Prescription finality differs from a retail return

The refund policy makes prescription sales final once payment has been charged and the package has been handed to the carrier. It permits portal changes or cancellation before shipping. Confirm a cancellation’s financial effect before assuming any paid prescription is refundable.⁵

The policy’s possible 30-day return applies only to unopened nonprescription products, with customer-paid return shipping and approval after inspection. It is not a tirzepatide return window. For a package lost in transit, the policy describes carrier tracing and reshipment; report damage or loss promptly.⁵

Public partner names do not settle personal assignment

The FAQ names Telegra as a provider network and Boudreaux’s New Drug Store as a Louisiana pharmacy it describes as licensed under 503A, preparing patient-specific compounds and shipping where permitted. These are attributed public disclosures, not independent verification of current credentials or the facility assigned to an individual order.⁴

Confirm current service availability in your state and the actual treating practice before payment. Compounded tirzepatide is not an FDA-approved finished drug, and neither a partner name nor a general regulatory statement establishes a product’s approval or equivalence.^4,7 Brand-drug trials do not establish outcomes for this platform or a compounded preparation. SURMOUNT-1 and SURMOUNT-5 provide clinical context, not proof that a particular compounded formulation or care program produces the same results.^1,2

Further reading

compounded tirzepatide legal status · Zepbound side effects · gallbladder risk · thyroid cancer warning · tirzepatide evidence guide · ondra health review · compare tirzepatide providers